Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 9 10 11 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors 2022-07-13
Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m 2022-07-13
Corat Therapeutics–Germany (govt): grant, 202207– up to €38.7m funding from BMBF for pivotal trial of Covid-19 drug candidate COR-101 2022-07-13
Mosanna Therapeutics–Forty51 Ventures: investment, 202207 seed financing round incl lead investor + co-founder Forty51 Ventures 2022-07-13
Mosanna Therapeutics–SEVERAL: investment, 202207 seed financing round led by Forty51 Ventures 2022-07-13
4D Lifetec–SEVERAL: investment, 202207 financing round Series B CHF1.9m first closing from existing + new investors + strategic partners 2022-07-11
Swedish Orphan Biovitrum–ADC Therapeutics: loncastuximab tesirine-lpyl, 202207– license excl $55m upfront + $710m milestones outside US+China+SG+JP 2022-07-08
Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF 2022-07-07
Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF 2022-07-07
Aurobac Therapeutics–Boehringer: investment, 202207 launch of €40m joint venture Aurobac incl €30m from lead investor Boehringer Ingelheim 2022-07-06
BeiGene–InnoRNA: mRNA therapies, 202207– collab strategic r+d ww using InnoRNA LNP-based delivery technology with ww rights for BeiGene 2022-07-06
Boehringer–Evotec: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor Evotec 2022-07-06
Boehringer–Mérieux: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor bioMérieux 2022-07-06
Life Science Valley–Lower Saxony (govt): grant, 202207–202412 project grant funding €5m with €2m for business incubator + €3m directly for start-ups 2022-07-01
Pepscan–Biosynth Carbosynth: investment, 202206 acquisition of Pepscan by Biosynth Carbosynth 2022-06-30
Molzym–OTHER: investment, 202206 investment 2-digit €m from large single family office 2022-06-29
Green Generation–SEVERAL: investment, 202206 fund launched with €100m raised 2022-06-28
Verve Capital Partners–SEVERAL: investment, 202206 1st CHF45m closing of Verve Venture Fund I 2022-06-24
F-Star–Sino Biopharm: investment, 202206– acquisition $161m cash tender offer by invoX Pharma at $7.12/share ANNOUNCED 2022-06-23
Ningaloo Biosystems–North Rhine-Westphalia (govt): investment, 202206 pre-seed financing round incl investor NRW.Bank 2022-06-22
Ningaloo Biosystems–OTHER: investment, 202206 pre-seed financing round incl team of business angels 2022-06-22
Ningaloo Biosystems–SEVERAL: investment, 202206 pre-seed financing round with business angels + NRW.Bank 2022-06-22
SPT Labtech–EQT: investment, 202206– acquisition £650m of SPT Labtech by EQT IX Fund from Battery Ventures 2022-06-22
Carma Fund–EU (govt): investment, 202206 first closing totalling €47m of Carma Fund I incl investor EIF 2022-06-21
Carma Fund–Evotec: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Evotec SE 2022-06-21
Carma Fund–Life Science-Stiftung: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Ascenion GmbH 2022-06-21
Carma Fund–Orbit Fund Boutique: legal services, 202206 supply service legal advise on fund structure 2022-06-21
Carma Fund–SEVERAL: investment, 202206 first closing €47m of Carma Fund I with target size of €60m 2022-06-21
Carma Fund–Univ Frankfurt: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Innovectis GmbH 2022-06-21
Novartis–Precision BioSciences: gene therapy, 202206– collab ww $50m upfront + $1.4b milestones + royalties using ARCUS platform to develop therapies 2022-06-21
Precision BioSciences–Novartis: investment, 202206 equity purchase $25m at $2.01/share in connection with collaboration 2022-06-21
Kranus Health–A Round Capital: investment, 202206 financing round Series A totalling >$6.5m incl existing + co-investor A Round Capital 2022-06-20
Kranus Health–High-Tech Gründerfonds: investment, 202206 financing round Series A totalling >$6.5m incl existing + co-investor HTGF 2022-06-20
Kranus Health–Karista: investment, 202206 financing round Series A totalling >$6.5m incl lead investor Karista 2022-06-20
Kranus Health–Peak Pride: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Peak Pride 2022-06-20
Kranus Health–PERSON: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Ehsan Khaljani 2022-06-20
Kranus Health–PERSON: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Florian Brand 2022-06-20
Kranus Health–Saarbruecker21: investment, 202206 financing round Series A totalling >$6.5m incl co-investor business angel group Saarbruecker21 2022-06-20
Kranus Health–SEVERAL: investment, 202206 financing round Series A >$6.5m led by Karista 2022-06-20
Valneva–Pfizer: investment, 202206 equity investment via capital increase €90.5m (representing 8.1% if capital) at €9.49/share 2022-06-20
Ymmunobio–Yumab: cancer antibody drug, 202206– collab €na optimisation of CEACAM antibodies by Yumab 2022-06-16
High-Tech Gründerfonds–SEVERAL: investment, 202206 1st closing of HTGF IV at more than €400m incl BMWK + KfW Capital 2022-06-14
JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica 2022-06-14
ImCheck Therapeutics–Bellevue: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Pureos Bioventures 2022-06-13
ImCheck Therapeutics–Boehringer: investment, 202206 financing round Series C totalling €80m incl existing + co-investor BIVF 2022-06-13
ImCheck Therapeutics–Earlybird: investment, 202206 financing round Series C totalling €80m incl new + co-lead investor Earlybird 2022-06-13
ImCheck Therapeutics–SEVERAL: investment, 202206 financing round Series C €80m co-led by new investors Earlybird + Andera Partners 2022-06-13
ImCheck Therapeutics–Wellington Partners: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Wellington Partners 2022-06-13
ModuVision–Knauer: investment, 202206 acquisition of ModuVision by Knauer 2022-06-13
Forbion–SEVERAL: investment, 202206 first close €470m of Forbion Growth Opportunities Fund II with target size of €600m hard cap 2022-06-09
Peptone–Novartis: investment, 202206 financing round Series A totalling $40m incl existing + co-investor dRX Capital 2022-06-09
Peptone–Nvidia: AI-based drug discovery, 202206 collab incl use of Nvidia DGX A100 supercomputer to run Peptone’s algorithmic engine 2022-06-09
Peptone–SEVERAL: investment, 202206 financing round Series A $40m led by F-Prime + Bessemer Venture Partners 2022-06-09
Relation Therapeutics–PERSON: investment, 202206 seed financing round totalling $25m incl co-investor Peer Schatz 2022-06-09
Relation Therapeutics–SEVERAL: investment, 202206 seed financing round $25m co-led by DCVC + Magnetic Ventures 2022-06-09
Ariceum Therapeutics–Bellevue: investment, 202206 financing round Series A totalling €25m incl co-investor Pureos Bioventures 2022-06-08
Ariceum Therapeutics–EQT: investment, 202206 financing round Series A totalling €25m incl co-founding + co-lead investor EQT Life Sciences 2022-06-08
Ariceum Therapeutics–Odlander Fredrikson: investment, 202206 financing round Series A totalling €25m incl co-founding + co-lead investor HealthCap 2022-06-08
Ariceum Therapeutics–Optimum Strategic Communications: public relations, 202206 service existent by Optimum 2022-06-08
Ariceum Therapeutics–SEVERAL: investment, 202206 financing round Series A €25m co-led by HealthCap + EQT Life Sciences 2022-06-08
BioVersys–SEVERAL: investment, 202206 financing round Series C first closing CHF24.2m from existing + new investors 2022-06-08
Frame Cancer Therapeutics–CureVac: investment, 202206 acquisition in shares €32m with €16m upfront + €16m milestones 2022-06-08
Mineralys Therapeutics–Andera Partners: investment, 202206 financing round Series B totalling $118m incl new + co-lead investor BioDiscovery 6 fund 2022-06-08
Mineralys Therapeutics–RA Capital: investment, 202206 financing round Series B totalling $118m incl new + co-lead investor RA Capital Management 2022-06-08
Mineralys Therapeutics–SEVERAL: investment, 202206 financing round Series B $118m led by RA Capital + Andera Partners 2022-06-08
Immatics–Editas Medicine: CRISPR technology, 202206– collab strategic research + license €na for use of CRISPR with ACTallo cell therapy platform 2022-06-07
ImmunOs Therapeutics–BioMedPartners: investment, 202206 financing round Series B totalling $74m incl existing + co-investor BioMedPartners 2022-06-07
ImmunOs Therapeutics–Fiscus Financial: investment, 202206 financing round Series B totalling $74m incl new + co-investor Fiscus Financial 2022-06-07
ImmunOs Therapeutics–Gimv: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Gimv 2022-06-07
ImmunOs Therapeutics–GL Capital: investment, 202206 financing round Series B totalling $74m incl new + co-investor GL Capital 2022-06-07
ImmunOs Therapeutics–Lightspeed Venture Partners: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Lightspeed VP 2022-06-07
ImmunOs Therapeutics–Mission BioCapital: investment, 202206 financing round Series B totalling $74m incl new + co-investor Mission BioCapital 2022-06-07
ImmunOs Therapeutics–Peak6 Strategic Capital: investment, 202206 financing round Series B totalling $74m incl new + co-investor Peak6 2022-06-07
ImmunOs Therapeutics–Pfizer: investment, 202206 financing round Series B totalling $74m incl existing + co-investor Pfizer Ventures 2022-06-07
ImmunOs Therapeutics–Samsara BioCapital: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Samsara BioCapital 2022-06-07
ImmunOs Therapeutics–Schroders: investment, 202206 financing round Series B totalling $74m incl existing + co-investor Schroder Adveq 2022-06-07
ImmunOs Therapeutics–SEVERAL: investment, 202206 financing round Series B $74m led by Samsara BioCapital + Lightspeed VP + Gimv 2022-06-07
Invasight–Avanteca Partners: investment, 202206 seed financing round totalling CHF4.5m incl co-investor Avanteca Partners 2022-06-07
Invasight–High-Tech Gründerfonds: investment, 202206 seed financing round totalling CHF4.5m incl co-investor HTGF 2022-06-07
Invasight–Occident: investment, 202206 seed financing round totalling CHF4.5m incl lead investor Occident 2022-06-07
Invasight–OTHER: investment, 202206 seed financing round totalling CHF4.5m incl angel investors 2022-06-07
Invasight–SEVERAL: investment, 202206 seed financing round CHF4.5m led by Occident 2022-06-07
Invasight–Univ Basel: investment, 202206 seed financing round totalling CHF4.5m incl co-lead investor JFG Life Sciences Foundation 2022-06-07
Invasight–Verve Capital Partners: investment, 202206 seed financing round totalling CHF4.5m incl co-investor Verve Ventures 2022-06-07
Invasight–Wille Finance: investment, 202206 seed financing round totalling CHF4.5m incl co-investor Wille Finance AG 2022-06-07
Invasight–Zürcher Kantonalbank: investment, 202206 seed financing round totalling CHF4.5m incl co-investor ZKB 2022-06-07
BMS–Immatics: cancer immunotherapy, 202201– collab strategic alliance expansion $60m upfront + $700 milestones per programme using ACTallo platform 2022-06-02
Merck (DE)–Proxygen: molecular glue degraders, 202206– strategic multi-year collab + license agreem up to €495m plus royalties 2022-06-02
Upstream Bio–HBM: investment, 202206 financing round Series A totalling $200m incl co-investor HBM Healthcare Investments 2022-06-02
Upstream Bio–SEVERAL: investment, 202206 financing round Series A $200m co-led by OrbiMed + Maruho Co Ltd 2022-06-02
Agilent–Mettler-Toledo: lab automation, –202206 collab developm + product integration automated + digitalised sample prep for LC/GC workflow 2022-06-01
Roche–Repare Therapeutics: ATR inhibitor, 202206– 202402 ww license + collab camonsertib $125m upfront + $1.2b milestones + royalties TERMINATED 2/24 2022-06-01
Firmenich–DSM: investment, 202205– merger with former DMS owners holding 65.5% + Firmenich owners receiving 34.5% plus €3.5b in cash ANNOUNCED 2022-05-31
Minoryx–SEVERAL: credit, 202205 complementary bank debt to Series C financing round (both tog totalling €51m) 2022-05-31
Minoryx–SEVERAL: investment, 202205 financing round Series C (incl complementary bank totalling €51m) led by Columbus VP + Caixa Capital Risc 2022-05-31
Partex–Merck (DE): MetAP2 inhibitor, 202205– license to M8891 to Cureteq for AI-based development by Oncoteq from Merck KGaA 2022-05-30
Rigenerand–Evotec: investment, 202205–202207 acquisition 100% for €23m 2022-05-30
Rigenerand–Xyence Capital: investment, 202205 existent Xyence is majority shareholder at time of sale of Rigenerand to Evotec 2022-05-30
Irubis–EU (govt): grant, 202005– grant €1.3m from EIC Accelerator Pilot Programme 2022-05-26
Aalto Bio Reagents–Biosynth Carbosynth: investment, 202205 acquisition of Aalto by Biosynth Carbosynth 2022-05-25
next pagenext page 1 2 3 ... 9 10 11 ... 33 34 35  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top